Hemostemix (CVE:HEM) Shares Up 38.1% – Still a Buy?

Hemostemix Inc. (CVE:HEM)’s stock price was up 38.1% on Wednesday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares traded hands during mid-day trading, an increase of 56% from the average daily volume of 387,760 shares. The stock had previously closed at C$0.11.

Hemostemix Stock Up 38.1 %

The firm has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20. The business’s 50-day simple moving average is C$0.09 and its 200 day simple moving average is C$0.07.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.